How BMS Is Tackling Clinical Trial Diversity
Site Selection Is A Critical Component
Executive Summary
The company’s director of clinical trial diversity strategy, Lorena Kuri, talked to Scrip about how she became interested in trial diversity and what BMS is doing to increase it.
You may also be interested in...
OCE ‘Project’ To Help Understand Trial Site Selection, Also May Inform Policy
Project Site Selector will allow FDA Oncology Center of Excellence staff to discuss site selection process with industry and potentially help improve clinical trial diversity efforts.
Has There Been A Sea Change In Trial Diversity Efforts?
PhRMA partnered with Deloitte to produce a report that included a survey of 31 member companies indicating that most had made significant investments in improving clinical trial diversity.
Database In Works To Help Drugmakers Avoid Molecules That Trigger Immune Reactions
Individuals from pharma, biotech, technology and academia create shared database to facilitate development of therapeutic proteins that are unlikely to provoke immune reactions.